Back to Search
Start Over
VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing.
- Source :
-
Journal of orthopaedic research : official publication of the Orthopaedic Research Society [J Orthop Res] 2019 Jun; Vol. 37 (6), pp. 1294-1302. Date of Electronic Publication: 2018 Nov 30. - Publication Year :
- 2019
-
Abstract
- A significant number of fractures develop non-union. Mesenchymal stem cell (MSC) therapy may be beneficial, however, this requires cell acquisition, culture and delivery. Endogenous mobilization of stem cells offers a non-invasive alternative. The hypothesis was administration of VEGF and the CXCR4 antagonist AMD3100 would increase the circulating pool of available MSCs and improve fracture healing. Ex-breeder female wistar rats received VEGF followed by AMD3100, or sham PBS. Blood prepared for culture and colonies were counted. P3 cells were analyzed by flow cytometry, bi-differentiation. The effect of mobilization on fracture healing was evaluated with 1.5 mm femoral osteotomy stabilized with an external fixator in 12-14 week old female Wistars. The mobilized group had significantly greater number of cfus/ml compared to controls, p = 0.029. The isolated cells expressed 1.8% CD34, 35% CD45, 61% CD29, 78% CD90, and differentiated into osteoblasts but not into adipocytes. The fracture gap in animals treated with VEGF and AMD3100 showed increased bone volume; 5.22 ± 1.7 µm <superscript>3</superscript> and trabecular thickness 0.05 ± 0.01 µm compared with control animals (4.3 ± 3.1 µm <superscript>3</superscript> , 0.04 ± 0.01 µm, respectively). Radiographic scores quantifying fracture healing (RUST) showed that the animals in the mobilization group had a higher healing score compared to controls (9.6 vs. 7.7). Histologically, mobilization resulted in significantly lower group variability in bone formation (p = 0.032) and greater amounts of bone and less fibrous tissue than the control group. Clinical significance: This pre-clinical study demonstrates a beneficial effect of endogenous MSC mobilization on fracture healing, which may have translation potential to prevent or treat clinical fractures at risk of delayed or non-union fractures. © 2018 The Authors. Journal of Orthopaedic Research® Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res 37:1294-1302, 2019.<br /> (© 2018 The Authors. Journal of Orthopaedic Research1® Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society.)
- Subjects :
- Animals
Benzylamines
Cell Movement drug effects
Chemokine CXCL12 physiology
Cyclams
Female
Femoral Fractures diagnostic imaging
Femoral Fractures physiopathology
Mesenchymal Stem Cells physiology
Rats
Rats, Wistar
Receptors, CXCR4 antagonists & inhibitors
Receptors, CXCR4 physiology
X-Ray Microtomography
Femoral Fractures therapy
Fracture Healing drug effects
Heterocyclic Compounds pharmacology
Mesenchymal Stem Cells drug effects
Vascular Endothelial Growth Factor A pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1554-527X
- Volume :
- 37
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Journal of orthopaedic research : official publication of the Orthopaedic Research Society
- Publication Type :
- Academic Journal
- Accession number :
- 30345545
- Full Text :
- https://doi.org/10.1002/jor.24164